Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26242999 | 0.87 | ALDH1A1 (0.34) | ALDH1A1POLBCYP2D6CYP2C19HIF1A | |
| SCHEMBL3018592 | 0.86 | POLB (0.34) | ALDH1A1BRD4POLBPKMMME | |
| SCHEMBL19287544 | 0.83 | BRD4 (0.37) | ALDH1A1BRD4POLBCYP2C19PKM | |
| SCHEMBL23714721 | 0.81 | PTGS1 (0.43) | — | |
| SCHEMBL24854489 | 0.80 | CYP19A1 (0.36) | ALDH1A1POLBCYP19A1FKBP1A | |
| SCHEMBL24950149 | 0.80 | HDAC3 (0.37) | ALDH1A1POLBCYP19A1FKBP1A | |
| SCHEMBL18557347 | 0.79 | LMNA (0.43) | ALDH1A1POLBCYP2C19PKM | |
| SCHEMBL26049780 | 0.79 | ALDH1A1 (0.34) | ALDH1A1BRD4CYP2C19 | |
| SCHEMBL24228211 | 0.79 | HDAC3 (0.37) | ALDH1A1CYP2C19FKBP1A | |
| SCHEMBL25918038 | 0.79 | PAOX (0.38) | ALDH1A1CYP2C19CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148600-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148600-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | ALDH1A1 2554/4885BRD4 2913/4885POLB 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.